Published in Open Heart on May 16, 2017
Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J (2009) 8.25
Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals (The Malmo Preventive Project). Eur Heart J (2009) 2.58
2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm (2015) 2.54
Diagnostic criteria for vasovagal syncope based on a quantitative history. Eur Heart J (2005) 2.15
Lifetime cumulative incidence of syncope in the general population: a study of 549 Dutch subjects aged 35-60 years. J Cardiovasc Electrophysiol (2006) 1.79
The hemodynamic and neurohumoral phenotype of postural tachycardia syndrome. Neurology (2007) 1.77
Nexfin noninvasive continuous blood pressure validated against Riva-Rocci/Korotkoff. Am J Hypertens (2009) 1.64
'The Italian Protocol': a simplified head-up tilt testing potentiated with oral nitroglycerin to assess patients with unexplained syncope. Europace (2000) 1.43
Agonistic autoantibodies as vasodilators in orthostatic hypotension: a new mechanism. Hypertension (2012) 1.29
Age-related normative changes in phasic orthostatic blood pressure in a large population study: findings from The Irish Longitudinal Study on Ageing (TILDA). Circulation (2014) 1.23
Orthostatic Hypotension: Epidemiology, Prognosis, and Treatment. J Am Coll Cardiol (2015) 1.13
Influence of age and gender on the occurrence and presentation of reflex syncope. Clin Auton Res (2008) 1.11
History taking as a diagnostic test in patients with syncope: developing expertise in syncope. Eur Heart J (2014) 1.10
Mechanisms of atrial natriuretic peptide secretion from the atrium. Cardiovasc Res (2005) 1.07
Syndromes of orthostatic intolerance: a hidden danger. J Intern Med (2013) 1.00
Determination of catecholamines in human plasma by high-performance liquid chromatography: comparison between a new method with fluorescence detection and an established method with electrochemical detection. J Chromatogr (1989) 0.99
Twenty-eight years of research permit reinterpretation of tilt-testing: hypotensive susceptibility rather than diagnosis. Eur Heart J (2014) 0.98
High diagnostic yield and accuracy of history, physical examination, and ECG in patients with transient loss of consciousness in FAST: the Fainting Assessment study. J Cardiovasc Electrophysiol (2007) 0.98
Antiadrenergic autoimmunity in postural tachycardia syndrome. Europace (2016) 0.97
Decreased response of plasma renin activity to orthostasis in diabetic patients with orthostatic hypotension. Diabetes (1974) 0.91
Usefulness of plasma copeptin as a biomarker to predict the therapeutic effectiveness of metoprolol for postural tachycardia syndrome in children. Am J Cardiol (2014) 0.84
Orthostatic Changes in Hemodynamics and Cardiovascular Biomarkers in Dysautonomic Patients. PLoS One (2015) 0.83
Distinct neurohumoral biomarker profiles in children with hemodynamically defined orthostatic intolerance may predict treatment options. Am J Physiol Heart Circ Physiol (2015) 0.82
Clinical history in management of suspected syncope: A powerful diagnostic tool. Cardiol J (2014) 0.80
Role of atrial pressure and rate in release of atrial natriuretic peptide. Am J Physiol (1988) 0.80
Novel cardiovascular biomarkers in unexplained syncopal attacks: the SYSTEMA cohort. J Intern Med (2013) 0.79
Plasma copeptin and therapeutic effectiveness of midodrine hydrochloride on postural tachycardia syndrome in children. J Pediatr (2014) 0.77
Orthostatic hypotension of unknown cause: Unanticipated association with elevated circulating N-terminal brain natriuretic peptide (NT-proBNP). Heart Rhythm (2015) 0.77
Twelve-single nucleotide polymorphism genetic risk score identifies individuals at increased risk for future atrial fibrillation and stroke. Stroke (2014) 1.08
Use of low density lipoprotein particle number levels as an aid in statin treatment decisions for intermediate risk patients: a cost-effectiveness analysis. BMC Cardiovasc Disord (2016) 0.75
Fasting levels of growth hormone are associated with carotid intima media thickness but are not affected by fluvastatin treatment. BMC Cardiovasc Disord (2017) 0.75
A genetic risk score for CAD, psychological stress, and their interaction as predictors of CAD, fatal MI, non-fatal MI and cardiovascular death. PLoS One (2017) 0.75
Metabolic Mediators of the Effects of Family History and Genetic Risk Score on Coronary Heart Disease-Findings From the Malmö Diet and Cancer Study. J Am Heart Assoc (2017) 0.75
Genetic Interactions with Age, Sex, Body Mass Index, and Hypertension in Relation to Atrial Fibrillation: The AFGen Consortium. Sci Rep (2017) 0.75
Cardiovascular risk after hospitalisation for unexplained syncope and orthostatic hypotension. Heart (2017) 0.75